MG 4101

Drug Profile

MG 4101

Alternative Names: Allogeneic NK cells; MG4101

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Green Cross
  • Developer Green Cross; Samsung Medical Center; Seoul National University Hospital
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Hepatocellular carcinoma; Solid tumours
  • No development reported Salivary gland cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma in South Korea (Parenteral, Injection)
  • 01 Nov 2017 Phase-II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in South Korea (IV) (NCT03349502)
  • 30 Sep 2016 Green Cross LabCell Corporation initiates enrolment in a phase II trial for Hepatocellular carcinoma in South Korea (NCT02854839)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top